We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

267 hedge funds and large institutions have $8.95B invested in Sage Therapeutics in 2019 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 132 increasing their positions, 59 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 59

90% more capital invested

Capital invested by funds: $4.71B → $8.95B (+$4.24B)

79% more call options, than puts

Call options by funds: $177M | Put options by funds: $98.9M

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 35

8% more funds holding

Funds holding: 248 → 267 (+19)

4.41% more ownership

Funds ownership: 106.12% → 110.53% (+4.4%)

Holders
267
Holders Change
+19
Holders Change %
+7.66%
% of All Funds
5.78%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.22%
New
55
Increased
132
Reduced
59
Closed
35
Calls
$177M
Puts
$98.9M
Net Calls
+$78.3M
Net Calls Change
+$42.5M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$219M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$197M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$83.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$78.7M
5
TCM
TimesSquare Capital Management
New York
+$71.7M

Top Sellers

1
Bank of New York Mellon
Bank of New York Mellon
New York
-$53.4M
2
PHS
PFM Health Sciences
California
-$48.7M
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$27.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$24.6M
5
EAM
Eventide Asset Management
Massachusetts
-$19M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$1.32B +$42.5M +293,304 +4%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.21B +$83.3M +575,163 +8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$726M +$78.7M +543,229 +14%
BlackRock
4
BlackRock
New York
$425M +$23.6M +162,976 +6%
Jennison Associates
5
Jennison Associates
New York
$375M +$219M +1,509,950 +179%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$351M +$41.3M +285,526 +15%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$265M +$197M +1,359,947 +441%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$233M -$53.4M -368,812 -20%
O
9
OppenheimerFunds
New York
$230M +$684K +4,721 +0.3%
BB
10
BB Biotech
Switzerland
$219M – – –
Franklin Resources
11
Franklin Resources
California
$167M +$899K +6,209 +0.6%
State Street
12
State Street
Massachusetts
$166M -$2.08M -14,390 -1%
JP Morgan Chase
13
JP Morgan Chase
New York
$151M +$76.2K +526 +0.1%
PAI
14
Palo Alto Investors
California
$136M +$971K +6,704 +0.8%
EAM
15
Eventide Asset Management
Massachusetts
$128M -$19M -131,000 -14%
Invesco
16
Invesco
Georgia
$108M +$6.53M +45,095 +7%
Lord, Abbett & Co
17
Lord, Abbett & Co
New Jersey
$98.7M +$71.4M +492,910 +386%
FCM
18
Farallon Capital Management
California
$95.4M +$29M +200,000 +50%
American Century Companies
19
American Century Companies
Missouri
$90.6M +$5.77M +39,835 +8%
Artisan Partners
20
Artisan Partners
Wisconsin
$89.4M +$45.2M +311,847 +125%
MWNA
21
Marshall Wace North America
New York
$86M +$7.78M +53,704 +11%
EAM
22
Eagle Asset Management
Florida
$85.2M -$16.2M -111,670 -17%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$83.5M +$8.24M +56,869 +12%
TCM
24
TimesSquare Capital Management
New York
$78.8M +$71.7M +495,200 New
AllianceBernstein
25
AllianceBernstein
Tennessee
$71.1M -$3.54M -24,457 -5%
1
2 3 4 5

SAGE Hedge Fund Activity: Q1 2019 in Review

267 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2019, worth a combined $8.95B — up 90% from $4.71B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new SAGE positions and 35 closed out — a net gain of 20 holders — while 132 added to existing stakes and 59 trimmed.

The largest buyer was Jennison Associates, adding an estimated $219M. The largest seller was Bank of New York Mellon, cutting an estimated $53.4M.

  • 267 institutional investors held Sage Therapeutics (SAGE) as of Q1 2019, up from 248 in Q4 2018.
  • Funds reported $8.95B of Sage Therapeutics stock for Q1 2019, up 90% quarter-over-quarter.
  • 55 funds opened new Sage Therapeutics positions in Q1 2019 and 35 closed out, a net change of +20 holders.
  • The largest Sage Therapeutics buyer in Q1 2019 was Jennison Associates, an estimated $219M added.
  • The largest Sage Therapeutics seller in Q1 2019 was Bank of New York Mellon, an estimated $53.4M sold.

Based on aggregated 13F filings for Q1 2019.